Welcome to our dedicated page for Staar Surg news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surg stock.
STAAR Surgical Company (NASDAQ: STAA) features prominently in ophthalmic and corporate news due to its focus on implantable intraocular lenses and its role in the vision correction market. Company press releases describe STAAR as the global leader in implantable phakic intraocular lenses, particularly through the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, and as a long-standing participant in ophthalmic surgery since 1982.
This news page aggregates coverage related to STAAR’s product developments, strategic decisions, shareholder actions, and governance changes. Recent announcements include the proposed and later terminated merger agreement with Alcon, a series of special meetings and proxy solicitations, and a cooperation agreement with major shareholder Broadwood Partners under which representatives of Broadwood and Yunqi Capital joined STAAR’s Board of Directors. These events illustrate how transaction activity and shareholder perspectives can influence the company’s direction while it continues to operate as a standalone, publicly traded company on Nasdaq.
Readers can expect updates on topics such as merger and acquisition proposals, outcomes of shareholder votes, board appointments, and other material events reported in STAAR’s press releases and related communications. Because STAAR’s core business centers on ophthalmic surgical products like Implantable Collamer Lenses and intraocular lenses, news may also highlight the positioning of its EVO ICL technology and its use in vision correction procedures in markets around the world.
For investors, analysts, and industry observers, following STAA news offers insight into both the company’s ophthalmic product strategy and its evolving governance and ownership dynamics. This page provides a centralized view of those developments as they are reported in official company and market communications.
Alcon (SIX/NYSE: ALC) announced an amended merger agreement to acquire STAAR Surgical (NASDAQ: STAA) for $30.75 per share in cash, increasing the offer by roughly $150 million of equity value. The transaction represents an approximate $1.6 billion total equity value, a 74% premium to STAAR’s 90-day VWAP and a 66% premium to STAAR’s August 4, 2025 closing price.
Alcon said it will finance the deal with short- and long-term credit facilities, expects the merger to be accretive to earnings in year two, and anticipates closing in early 2026, subject to regulatory and STAAR stockholder approvals. STAAR stockholders are urged to vote ahead of a December 19, 2025 meeting.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
STAAR Surgical (NASDAQ: STAA) and Alcon (NYSE: ALC) agreed amendments to their merger agreement that create a new 30-day go-shop allowing STAAR to solicit third-party proposals through December 6, 2025. Under the amendment, Alcon waives matching rights and limited information rights during the go-shop, and STAAR will not pay a termination fee if it accepts a superior qualified proposal.
The companies said Alcon will engage with STAAR stockholders and proxy advisors. STAAR postponed its Special Meeting to vote on the merger to December 19, 2025 (previously December 3, 2025); stockholders of record as of October 24, 2025 remain entitled to vote.
Yunqi Capital, a 5.1% STAAR Surgical (NASDAQ:STAA) shareholder, praised STAAR’s Q3 2025 results and urged STAAR’s board to terminate the proposed sale to Alcon (SIX/NYSE:ALC). Yunqi highlighted cost discipline: reported operating expenses of $59.4M, excluding $5.9M merger costs an implied run rate of $214M vs prior guidance of $225M. Cash, cash equivalents and investments rose to $192.7M from $189.9M sequentially. Yunqi says China ICL demand recovered, disputes Alcon’s selective use of IQVIA and McKinsey data, and calls Alcon’s $28/share proposal opportunistic. Yunqi notes ~72% of outstanding STAAR shares reportedly voted against the deal as of Oct 23, 2025, and offers to join the board to add shareholder perspective.
STAAR Surgical (NASDAQ: STAA) reported Q3 2025 net sales of $94.7M, up 6.9% year-over-year, including a one-time $25.9M recognition from a December 2024 China shipment paid in full in Q3. Excluding China, sales were $38.9M, up 7.7% Y/Y. Gross margin improved to 82.2% from 77.3% a year ago, driven by timing on the China shipment and cost reductions. Adjusted EBITDA rose to $34.6M ($0.68/sh) from $16.2M. GAAP net income was $8.9M ($0.18/sh) versus $10.0M a year ago. Cash and investments totaled $192.7M and the company had no debt. The company repurchased ~115k shares for $2.0M in Q3 and will not host a conference call due to a pending Alcon acquisition.
Broadwood Partners (investor in STAAR Surgical, NASDAQ:STAA) on Nov 4, 2025 urged shareholders to vote AGAINST Alcon’s (NYSE:ALC) proposed acquisition of STAAR. Broadwood says it owns 27.5% of STAAR and criticizes an Alcon presentation as "fallacious" and misleading, arguing the STAAR board should not delay the shareholder vote or seek Alcon’s permission to run a strategic process. Broadwood cites what it describes as broad shareholder and proxy-advisor opposition to the deal and highlights prior procedural adjournments of STAAR’s Special Meeting. The statement frames the transaction as distracting and harmful to STAAR’s business and directs shareholders to a campaign site for more information.
Summary not available.